CA2778081A1 - Devices, methods, and composition for controlling infections - Google Patents
Devices, methods, and composition for controlling infections Download PDFInfo
- Publication number
- CA2778081A1 CA2778081A1 CA2778081A CA2778081A CA2778081A1 CA 2778081 A1 CA2778081 A1 CA 2778081A1 CA 2778081 A CA2778081 A CA 2778081A CA 2778081 A CA2778081 A CA 2778081A CA 2778081 A1 CA2778081 A1 CA 2778081A1
- Authority
- CA
- Canada
- Prior art keywords
- administration
- chlorhexidine
- solution
- wound
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 208000015181 infectious disease Diseases 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 14
- 239000000243 solution Substances 0.000 claims description 36
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 34
- 229960003260 chlorhexidine Drugs 0.000 claims description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 9
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 6
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 6
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 6
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 239000003708 ampul Substances 0.000 claims description 4
- 206010000269 abscess Diseases 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 238000012084 abdominal surgery Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000002262 irrigation Effects 0.000 abstract description 16
- 238000003973 irrigation Methods 0.000 abstract description 16
- 208000027418 Wounds and injury Diseases 0.000 description 52
- 206010052428 Wound Diseases 0.000 description 48
- 241000894006 Bacteria Species 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- KUXUALPOSMRJSW-IFWQJVLJSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 KUXUALPOSMRJSW-IFWQJVLJSA-N 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229940113601 irrigation solution Drugs 0.000 description 8
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 7
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000000820 nonprescription drug Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 208000034693 Laceration Diseases 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 229940064004 antiseptic throat preparations Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000222126 [Candida] glabrata Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003061 homeopathic agent Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000605036 Selenomonas Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The subject invention provides novel and highly effective methods and devices for convenient and effective wound irrigation.
Description
DESCRIPTION
DEVICES, METHODS, AND COMPOSITIONS FOR CONTROLLING INFECTIONS
CROSS-REFERENCE TO A RELATED APPLICATION
This application claims the benefit of U.S. provisional application Serial No.
61/254,906, filed October 26, 2009, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
In the management and treatment of a wound there are three primary objectives:
(1) prevention of infection, (2) preservation and/or restoration of function, and (3) preservation and/or restoration of cosmetic appearance. The most important of these objectives is the prevention of infection. Success in the prevention of infection directly affects the healing process and the degree to which function and cosmetic appearance can be preserved and/or restored.
However, heretofore, wound irrigation has not been directly combined with the administration of drugs that can reduce infection or otherwise promote healing.
It is known that the number of bacteria present at the site is a critical determinant of whether a wound becomes infected. Experimental evidence suggests that a critical level of bacteria is approximately 105 organisms per gram. of tissue. Below this level, wounds typically heal; at levels greater than 105 bacteria per gram of tissue, wounds often become infected. All traumatic wounds are contaminated by the time the wound is presented to a medical care facility for treatment (Dire, Daniel I. [1990] "A comparison of Wound Irrigation Solutions Used in the Emergency Department," Annals of Emergency Medicine 19(6):704-708). Dirty wounds, or those that have not been treated within six hours, are likely to be contaminated with bacteria at levels that are higher than the critical level. Reducing the number of bacteria in and around the wound is critical for avoiding infection and expediting wound healing.
Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by Staphylococcus aureus bacteria - often called "staph." Decades ago, strains of staph emerged in hospitals that were resistant to the broad-spectrum antibiotics commonly used to treat them.
DEVICES, METHODS, AND COMPOSITIONS FOR CONTROLLING INFECTIONS
CROSS-REFERENCE TO A RELATED APPLICATION
This application claims the benefit of U.S. provisional application Serial No.
61/254,906, filed October 26, 2009, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
In the management and treatment of a wound there are three primary objectives:
(1) prevention of infection, (2) preservation and/or restoration of function, and (3) preservation and/or restoration of cosmetic appearance. The most important of these objectives is the prevention of infection. Success in the prevention of infection directly affects the healing process and the degree to which function and cosmetic appearance can be preserved and/or restored.
However, heretofore, wound irrigation has not been directly combined with the administration of drugs that can reduce infection or otherwise promote healing.
It is known that the number of bacteria present at the site is a critical determinant of whether a wound becomes infected. Experimental evidence suggests that a critical level of bacteria is approximately 105 organisms per gram. of tissue. Below this level, wounds typically heal; at levels greater than 105 bacteria per gram of tissue, wounds often become infected. All traumatic wounds are contaminated by the time the wound is presented to a medical care facility for treatment (Dire, Daniel I. [1990] "A comparison of Wound Irrigation Solutions Used in the Emergency Department," Annals of Emergency Medicine 19(6):704-708). Dirty wounds, or those that have not been treated within six hours, are likely to be contaminated with bacteria at levels that are higher than the critical level. Reducing the number of bacteria in and around the wound is critical for avoiding infection and expediting wound healing.
Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by Staphylococcus aureus bacteria - often called "staph." Decades ago, strains of staph emerged in hospitals that were resistant to the broad-spectrum antibiotics commonly used to treat them.
These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin and amoxicillin. Dubbed methicillin-resistant Staphylococcus aureus (MRSA), it was one of the first germs to be resistant to all but the most powerful drugs.
Staph bacteria are generally harmless unless they enter the body through a cut or other wound. In older adults and people who are ill or have weakened immune systems, ordinary staph infections can cause serious illness. Staph infections, including MRSA, occur most frequently among persons in hospitals and healthcare facilities, such as nursing homes and dialysis centers, who have weakened immune systems.
In the 1990s, a type of MRSA began appearing in the wider community. Today, that form of staph, known as community-associated MRSA, or CA-MRSA, is responsible for many serious skin and soft tissue infections and for a serious form of pneumonia. When not treated properly, MRSA infection can be fatal.
MRSA infections are spreading rapidly in the United States and worldwide.
According to the Center for Disease Control and Prevention (CDC), the proportion of infections that are antimicrobial resistant has been growing. In 1974, MRSA infections accounted for two percent of the total number of staph infections; in 1995 it was 22%; and in 2004 it was nearly 63%.
Additionally, recent research has suggested that 30-50% of the population carries MRSA colonies on their bodies all the time, helping to facilitate the spread of infection.
Although MRSA has traditionally been seen as a hospital-associated infection, there has also been an epidemic of CA-MRSA in the United States. MRSA infections in the community are usually manifested as skin infections, such as pimples and boils. These CA-MRSA infections can occur in otherwise healthy people, and commonly occur among athletes who share equipment or personal items including towels and razors. In fact, from 2000 to present, there have been several reported outbreaks of CA-MRSA affecting high school athletic teams.
This epidemic among athletes is aided by the fact that MRSA grows very rapidly in warm, moist areas such as gyms and gym locker rooms. Common cuts and abrasions such as those frequently occurring in football and baseball now pose significant threats due to the possibility of an MRSA infection.
Vancomycin is one of the few antibiotics still effective against hospital strains of MRSA
infection, although the drug is no longer effective in every case. Several drugs continue to work against CA-MRSA, but CA-MRSA is a rapidly evolving bacterium, and it may be a matter of time before it, too, becomes resistant to most antibiotics.
Chlorhexidine is a chemical antiseptic, and it combats both gram positive and gram negative microbes. It is bacteriostatic, hampering the growth of bacteria, and bacteriocidal, killing bacteria. It is often used as an active ingredient in mouthwash designed to kill dental plaque and other oral bacteria. Chlorhexidine also has non-dental applications. For example, it is used for general skin cleansing, as a surgical scrub, and as a pre-operative skin preparation.
Chlorhexidine is typically used in the form of acetate, gluconate, or hydrochloride, either alone or in combination with other antiseptics such as cetrimide.
BRIEF SUMMARY OF THE INVENTION
The subject invention provides novel and highly effective methods, devices and compositions for efficient delivery of one or more medications or other active ingredients to a target site in a patient in order to reduce, prevent, and/or treat infection.
Examples of agents that can be administered to a patient in accordance with the subject invention include, but are not limited to, anti-bacterial agents, anti-viral agents, fungicidal agents, chemotherapy agents, topical antiseptics, anesthetic agents, oxygenated fluids and/or agents, antibiotics, diagnostic agents, homeopathic agents, and over the counter medications/agents. In a preferred embodiment, the active agent is Chlorhexidine gluconate, preferably at a concentration of less than 1.0%, more preferably less than 0.1% and most preferably at 0.05%
or less.
In one embodiment, the subject invention provides a reservoir housing containing an irrigation solution with one or more active agents, wherein the reservoir housing has attached to it a discharge means having one or a plurality of ports through which a sufficient volume of the solution can pass at an appropriate pressure for effective delivery of the solution, including the active agent, to a target site.
Staph bacteria are generally harmless unless they enter the body through a cut or other wound. In older adults and people who are ill or have weakened immune systems, ordinary staph infections can cause serious illness. Staph infections, including MRSA, occur most frequently among persons in hospitals and healthcare facilities, such as nursing homes and dialysis centers, who have weakened immune systems.
In the 1990s, a type of MRSA began appearing in the wider community. Today, that form of staph, known as community-associated MRSA, or CA-MRSA, is responsible for many serious skin and soft tissue infections and for a serious form of pneumonia. When not treated properly, MRSA infection can be fatal.
MRSA infections are spreading rapidly in the United States and worldwide.
According to the Center for Disease Control and Prevention (CDC), the proportion of infections that are antimicrobial resistant has been growing. In 1974, MRSA infections accounted for two percent of the total number of staph infections; in 1995 it was 22%; and in 2004 it was nearly 63%.
Additionally, recent research has suggested that 30-50% of the population carries MRSA colonies on their bodies all the time, helping to facilitate the spread of infection.
Although MRSA has traditionally been seen as a hospital-associated infection, there has also been an epidemic of CA-MRSA in the United States. MRSA infections in the community are usually manifested as skin infections, such as pimples and boils. These CA-MRSA infections can occur in otherwise healthy people, and commonly occur among athletes who share equipment or personal items including towels and razors. In fact, from 2000 to present, there have been several reported outbreaks of CA-MRSA affecting high school athletic teams.
This epidemic among athletes is aided by the fact that MRSA grows very rapidly in warm, moist areas such as gyms and gym locker rooms. Common cuts and abrasions such as those frequently occurring in football and baseball now pose significant threats due to the possibility of an MRSA infection.
Vancomycin is one of the few antibiotics still effective against hospital strains of MRSA
infection, although the drug is no longer effective in every case. Several drugs continue to work against CA-MRSA, but CA-MRSA is a rapidly evolving bacterium, and it may be a matter of time before it, too, becomes resistant to most antibiotics.
Chlorhexidine is a chemical antiseptic, and it combats both gram positive and gram negative microbes. It is bacteriostatic, hampering the growth of bacteria, and bacteriocidal, killing bacteria. It is often used as an active ingredient in mouthwash designed to kill dental plaque and other oral bacteria. Chlorhexidine also has non-dental applications. For example, it is used for general skin cleansing, as a surgical scrub, and as a pre-operative skin preparation.
Chlorhexidine is typically used in the form of acetate, gluconate, or hydrochloride, either alone or in combination with other antiseptics such as cetrimide.
BRIEF SUMMARY OF THE INVENTION
The subject invention provides novel and highly effective methods, devices and compositions for efficient delivery of one or more medications or other active ingredients to a target site in a patient in order to reduce, prevent, and/or treat infection.
Examples of agents that can be administered to a patient in accordance with the subject invention include, but are not limited to, anti-bacterial agents, anti-viral agents, fungicidal agents, chemotherapy agents, topical antiseptics, anesthetic agents, oxygenated fluids and/or agents, antibiotics, diagnostic agents, homeopathic agents, and over the counter medications/agents. In a preferred embodiment, the active agent is Chlorhexidine gluconate, preferably at a concentration of less than 1.0%, more preferably less than 0.1% and most preferably at 0.05%
or less.
In one embodiment, the subject invention provides a reservoir housing containing an irrigation solution with one or more active agents, wherein the reservoir housing has attached to it a discharge means having one or a plurality of ports through which a sufficient volume of the solution can pass at an appropriate pressure for effective delivery of the solution, including the active agent, to a target site.
DETAILED DESCRIPTION OF THE INVENTION
The subject invention provides novel, convenient, inexpensive, and effective drug delivery techniques that utilize, in one embodiment, a device having a reservoir housing and a discharge means for delivering an active agent to a target site. The subject invention also provides compositions and methods of use for the device and composition.
The materials and methods of the subject invention make it possible to conveniently and easily apply fluid containing, for example, a medicinal agent to, for example, a wound. In one embodiment the wound is a surgical site.
As used herein, "active agents" refers to compounds or other entities that perform a therapeutic and/or diagnostic function. This function may be direct, such as promoting tissue repair or killing cancer cells, or may be indirect by eliciting a physiological response that ultimately results in the desired beneficial result.
In one embodiment, a sterile water (not saline) solution comprising 0.05% or less (or even less than 0.04% or even less than 0.03%) of chlorhexidine is applied to a wound in the skin of a human. Preferably the wound is then rinsed within five minutes (preferably within 1-3 )minutes) with a sterile saline or water liquid that does not contain chlorhexidine.
In another embodiment, the solution is applied to a surgical site.
In a specific embodiment, the chlorhexidine gluconate used according to the subject invention has the following chemical structure:
HN
HN H
Chiorhexidine Gluconate Systematic 1- [amino- [6- [amino- [amino-(4-chlorophenyl)amino (JUPAC) Name methylidene]amino-methylidene]aminohexylimino]
methyl] imino-N- (4-chlorophenyl)-methanedi ami ne Chemical Data Formula C22H30C12Nio Mol. weight 505.446 g/rnol In a preferred embodiment, about 15-25 mg of chlorhexidine gluconate is applied to a wound. In one embodiment, the woimd is an abrasion or laceration and the solution is applied prior to repair/closure.
Preferably, the pH of the solution is neutral or slightly acidic. Preferably the pH is 5.0 to 7.5. More preferably the pII is 5.5. to 7Ø In one embodiment, the chlorhexidine is applied without a sudsing agent.
In certain embodiments, the composition does not have any ingredients that would promote microbial growth. Preferably, the composition does not comprise a consistency builder as that term is used in U.S. Published Application 2007/0184114, which is incorporated herein in its entirety.
In specific embodiments, a CHG-containing solution is applied to an open surgical wound. The solution may be applied under pressure or not under pressure. In one embodiment, the solution is not applied by jet lavage. In a further embodiment, the fluid is not applied under pressure. Preferably, the patient is a human. The patient may also be, for example, a dog, horse, cat, pig or cattle.
Preferably, after administration of the CHG solution, the site is washed with saline within 1, 5, or 10 minutes.
In the context of the operating room, the CHG-containing solution is preferably in a sterile container. The container may be sterilized by, for example, irradiation.
In one embodiment, CHG may be provided in a small ampule such that the contents of the ampule can be added to, for example, a standard sized bottle of water, or to an IV bag or line, to create a CHG solution having a concentration of CIIG as described herein.
The solution of the subject invention can also be provided in an IV bag.
In other embodiments, the subject invention provides antimicrobial lotions, creams, sponges, and suppositories. These embodiments preferably contain CHG as the active ingredient.
These embodiments provide CHG, at the concentrations set forth herein, directly to a location wherein antimicrobial activity is needed.
The aqueous solution containing CHG may have other components including, for example, pII modifiers, buffers, local anesthetic agents, agents that promote wound healing (such as agents that help degrade biofilm) and other therapeutic and non-therapeutic compounds. In one embodiment, the composition "consists essentially" of an aqueous solution of CHG, which means that the solution contains no other active agent that materially changes the ability of the solution to control bacteria growth.
In a preferred embodiment, the wound is rinsed with saline after application of a CHG-containing solution. Rinsing with saline not only rinses the CHG off but also the saline chemically neutralizes the CHG thereby preventing or reducing edema. The rinse is preferably applied about 30 seconds to about 5 minutes after the administration of the CHG. The rinse may be from about 100 ml to 1000 ml of saline and is typically applied for about 5 seconds to about 1 minute.
In a preferred embodiment, the application of the irrigation solution of the subject invention results in a reduction in the number of bacteria at the wound when compared to either an untreated wound or a wound irrigated with saline or water that does not contain chlorhexidine.
Advantageously, the use of CHG according to the subject invention can result in effective control of an infection without causing tissue damage.
Advantageously, the irrigation solution of the subject invention i s effective in combating infection, even when organic materials (including blood, tissue, and/or dirt and debris) are present. Of course, such materials are present in all skin wounds.
In addition to killing bacteria, the formulations of the subject invention can also "depathogenize" certain bacteria including, for example, E. coli and Klebsiella aerogenes, making these bacteria less able to cause infection.
Advantageously, the compositions and methods of the subject invention can be used to effectively treat wounds even when biofilm is present.
The drug delivery methods of the subject invention can be used in conjunction with the delivery of an active agent by many of the routes set forth in Table 1. Of particular interest are:
cutaneous, intra-abdominal, intracranial, intralesional, intrathoracic (during surgery), irrigation, nasal, in the ear canal, as an oral bowel prep, for gastric lavage, as an eye wash, periodontal, rectal, soft tissue, subcutaneous, and vaginal routes. The compositions of the subject invention can also be used to control acne and other skin infections, including infections of the feet and scalp. In one embodiment, the chlorhexidine composition of the subject invention is used to treat an abscess. Preferably the solution is applied deep into the abscess using, for example, a device with an elongated discharge port to facilitate effective administration.
Under optimal circumstances, the drug delivery devices and methods of the subject invention are utilized by trained medical technicians; however, because of the simplicity and convenience of the devices of the subject invention, they can be used to greatly enhance the effectiveness of drug delivery regardless of the training level of the operator performing the irrigation.
Delivering Active Agents Examples of agents that can be administered to a patient in accordance with the subject invention include, but are not limited to, anti-bacterial agents, anti-viral agents, fungicidal agents, chemotherapy agents, topical antiseptics, anesthetic agents, oxygenated fluids and/or agents, antibiotics, diagnostic agents, homeopathic agents, and over-the-counter medications/agents.
The target sites to which an active ingredient can be administered according to the subject invention include, but are not limited to, wounds and surgical sites. The surgical sites may include, for example, joint replacements, abdominal surgery, brain surgery, and oral/periodontal surgery sites. In each case, the ability to deliver the active agent to a specific site, at an appropriate dosage, is unique and highly advantageous.
The solution that carries the active agent can be, for example, water, saline, or a balanced salt solution. The solution is preferably sterile. In the case of CHG, the solution is preferably water. The device can be sterilized by known sterilization techniques, including boiling, autoclaving, gas sterilization, irradiation, and the like, either separately or together with the reservoir housing.
The use of chlorhexidine is particularly advantageous because it is broad spectrum, binds to the skin (to provide residual activity), works rapidly and, when used according to the subject invention, is non-toxic.
Chlorhexidine is a chemical antiseptic that can be used to combat both gram positive and gram negative microbes. It is both bacteriostatic and bactericidal. Various species of bacteria are involved in the pathogenesis of wound infection and/or secondary cellulitis.
At times these infections can result in disfigurement, loss of extremities, prolonged convalescences, and/or death. The therapeutic effect of the irrigation solution of the subject invention is to combat microbes typically involved in the pathology of these infections by its antiseptic properties and those associated with the irrigation process itself. Controlling the microbial load in wounds is a vital factor in minimizing infection and thus decreasing and/or preventing disease.
Spectrum of Activity Chlorhexidine is active against aerobic and anaerobic gram-positive and gram-negative bacteria. The drug also has some activity against Chlamydia trachomatis, certain fungi, and certain viruses.
Aerobic Bacteria Chlorhexidine is highly active against a variety of gram-positive aerobic bacteria, including Streptococcus mutans, S pyogenes (group A (3-hemolytic streptococci), S. salivarius, and S. sanguis. Chlorhexidine is active against Staphylococcus aureus, S.
epidermidis, S.
haemolyticus, S. hominis, and S. simulans. The drug is active against both oxacillin-resistant (ORSA) and oxaeillin-susceptible staphylococci (also known as methicillin-resistant [MRSA] or methicillin-susceptible staphylococci). Chlorhexidine is active against Enterococcus, including E. faecalis and E.faecium, and is active against both vancomycin-susceptible and vancomycin-resistant strains.
Anaerobic Bacteria Chlorhexidine is active against some anaerobic bacteria. The drug is active against some strains of Bacteroides, Propionibacterium, Clostridium difficile, and Selenomonas, but is less active against Veillonella.
Fungi Chlorhexidine has some activity against Candida albicans, C. dubliniensis, C.
glabrata (formerly Torulopsis glabrata), C. guillermondii, C. kefyr (formerly C.
pseudotropicalis), C.
krusei, C. lusitaniae, and C. tropicalis (formerly C. parapsilosis).
Chlorhexidine also has some activity against dermatophytes, including Epidermophyton floccosum, Microsporum gypseum, M. cans, and Trichophyton mentagrophytes.
Viruses Chlorhexidine appears to have antiviral activity against viruses that have a lipid component in their outer coat or have an outer envelope such as cytomegalovirus (CMV), human immunodeficiency virus (HIV), herpes simplex virus types 1 (HSV-l) and 2 (HSV-2), influenza virus, parainfluenza virus, and variola virus (smallpox virus).
Methods and Formulations Advantageously, because the methods of the subject invention can be used to accurately and efficiently deliver an active ingredient to a target site in a patient, it is possible, in certain embodiments, to utilize reduced concentrations of active ingredients. Thus, in one embodiment of the subject invention, a low concentration solution of chlorhexidine can be used to effectively reduce infections at, for example, a wound, surgical site, or other tissue opening. In a preferred embodiment, the chlorhexidine solution is less than 4%. In a more preferred embodiment the chlorhexidine is less than 2%, or less than 1 % or even less than 0.1 %. In one embodiment, the chlorhexidine solution is 0.05%. In a further embodiment, the chlorhexidine solution is between 0.02% and 0.05%. Specifically exemplified herein is the use of chlorhexidine gluconate.
As described above, in one embodiment of the subject invention, the device of the subject invention is used to deliver an active agent, such as an antimicrobial agent, to a target site, such as a wound. Subsequent to the administration of the active agent, the site can then be flushed with, for example, saline to remove at least any excess of the active agent.
Preferably, this flushing occurs within five minutes of the administration of the chlorhexidine solution. More preferably, this flushing occurs within one to three minutes of the administration of the chlorhexidine solution. In this way, any potential toxicity associated with the active agent can be reduced or eliminated. In the case of chlorhexidine gluconate, rinsing with an irrigation fluid removes excess chlorhexidine that has not bound to, for example, proteins of the skin.
In yet another embodiment, a diagnostic agent can be administered using the device and method of the subject invention. The diagnostic agent may be, for example, an antibody, protein, or polynucleotide that binds to a target biomolecule. Any such binding may then be visualized utilizing technologies known to those skilled in the art. These technologies include, for example, the use of flourophores or other labels that can be visualized either by the naked eye or through appropriate detection instruments. The diagnostic applications of the subject invention include the detection of bacteria, viruses, parasites and other pathogens.
Cancer cells can also be visualized using the diagnostic methods of the subject invention.
In yet another embodiment, the device and method can be used to deliver growth factors and/or protease inhibitors to a target site. Such growth factors and/or protease inhibitors, which can, for example, expedite the healing of wounds, are well known to those skilled in the art.
In yet another embodiment, the method of the subject invention can be used to deliver oxygenated water and/or "enhanced water" to a target site. The enhanced water can be that which is described in, for example, published U.S. Patent Application 20050191364 and the references cited therein (all of which are incorporated herein by reference in their entireties). The use of the subject method for the effective delivery of such oxygenated or enhanced water can be used to promote tissue healing and reduce infections.
In a further embodiment, the device and method of the subject invention can be used to efficiently deliver anti-microbial peptides (AMPs) to a target site. AMPs are well known in the art. Antimicrobial peptides are predominantly small polypeptides that inhibit the growth of microbes. As effectors of innate immunity, antimicrobial peptides directly kill a broad spectrum of bacteria, fungi, and viruses. In addition, these peptides modify the local inflammatory response and activate mechanisms of cellular and adaptive immunity.
Cathelicidins and defensins comprise the major families of AMPs in the skin, although other cutaneous peptides, such as proteinase inhibitors, chemokines, and neuropeptides, also demonstrate antimicrobial activity. See, for example, Praff, M. et al., (2005) "Cutaneous Defense Mechanisms by Antimicrobial Peptides," .Ilnvest Dermatol, 125:9-13.
The Drug Delivery Device The device of the subject invention can be, for example, the device as shown in U.S.
Published Application No. US-2008-0159963-Al, which is incorporated herein, in its entirety, by reference. The reservoir may be, for example, from 100 ml to 1000 ml.
In one embodiment, the subject invention provides a reservoir housing containing a solution with one or more active agents, wherein the reservoir housing has attached to it a discharge means having one or a plurality of ports through which a sufficient volume of the solution can pass at an appropriate pressure for effective delivery of the solution, including the active agent, to a target site.
The reservoir housing and contents can be stored in a sterile environment, e.g., sterile packaging which is opened immediately prior to use. The reservoir housing can be directed towards the wound and squeezed or compressed to expel or discharge the solution in the desired direction, and at the desired pressure to effect irrigation of a wound to remove contaminants or debris and to deliver the active agent(s).
The discharge means can be packaged separately from the reservoir housing. The discharge means is packaged in a sterile environment. In one embodiment, the drug delivery device is provided in a sterile tray. According to the subject invention, the laceration tray can have, for example, in addition to the drug delivery device of the subject invention, other items conveniently provided for treating wounds. Contemplated items that can be included in a tray include, but are not limited to, needle holders (i.e., 5" floor-grade smooth);
scissors (i.e., 4.5"
floor-grade straight Iris scissors); hemostats (i.e., 5" floor-grade curved mosquito hemostat);
forceps (i.e., floor-grade tissue forceps with 1 x2 teeth); cups (i.e., 2 oz.
medicine cups); syringes (i.e., 10cc Luer Lock syringe); needles (i.e., 25 gauge x 5/8" needle; 27 gauge x 1.5" needle; 18 gauge x 1.5" needle); dressings (i.e., gauze dressings); drapes (i. e., polylined fenestrated drapes);
and towels (i.e., absorbent towels).
Significantly, it is known that more force is required to rid the wound of particles with a small surface area (e.g., bacteria) than to remove particles with a large surface area (e.g., dirt, sand, or vegetation). Minimum recommended volumes of irrigation solution vary, but for a moderately sized potentially contaminated wound, for example a laceration 3-6 cm long and less than 2 cm deep, at least 200 to 500 ml or more should be used. Greater volumes, on the order of 1.
one to two liters, may be required for larger or heavily contaminated wounds.
Irrigation should continue at least until all visible, loose particulate matter has been removed.
Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting.
When a patient presents a wound to a medical or other health care professional skilled in the art, that medical professional assesses the extent of the injury sustained by the patient, including all other life threatening injuries. Appropriate action regarding these life threatening injuries is performed and a history is recorded. All wounds are covered to minimize further contamination until the actual repair process begins.
For examination of the wound, it is assumed that a medical professional would have performed a detailed evaluation of the extent of tissue injury, including but not limited to:
anatomical area considerations, depth of the wound, type of injury, e.g., crash injury, puncture wound, bites, missiles, cuts with sharp objects, or the like. Included in this examination would be a determination of the type(s) of contamination, time elapsed between the occurrence of the injury to presentation, gross contamination of a wound, and other medical factors associated with an increased incidence of infection (for example, diabetics, AIDS patients, and chemotherapeutics patients).
The wound and surrounding tissue, at the option of the health care professional, could be anesthetized using topical, local, or general anesthetics before the wound-cleansing method begins. Alternatively, an anesthetic may be delivered using the device and method of the subject invention.
Manual or mechanically produced pressure is applied to the reservoir housing to expel the irrigation solution with active agent through the nozzles of the discharge means. The wound should be irrigated in this fashion until all visible evidence of contamination has been removed.
A potentially contaminated wound of any size should be irrigated with a minimum of 200-300 ml of irrigation solution. Heavily contaminated or larger wounds may require 2-3 liters of irrigation solution.
ollowing an initial irrigation of the wound, a re-examination of the wound should be undertaken. The wound should be explored to its base to ascertain that no visible foreign bodies or contaminants remain. If foreign bodies or contaminants are found, the irrigation process should be repeated followed by a re-examination. This may continue for several cycles.
Once irrigation has been completed, i.e., no visible contaminants remain, the damaged tissue would be repaired in a standard accepted fashion.
Irrigation of skin wounds such as cuts, scrapes, punctures, abrasions, etc.
are particularly well-suited for irrigation according to the subject invention, as is irrigation of surgical sites.
Table 1 provides a listing of various routes of administration that can be used according to the subject invention.
Table 1 - Routes of Administration Delivery Route Description AURICULAR (OTIC) Adm ire iistration to or by way of the ear.
BUCCAL Administration directed toward the cheek, generally from within the mouth.
CONJUNCTIVAL Administration to the conjunctiva, the delicate membrane that lines the eyelids and covers the exposed surface of the eyeball.
CUTANEOUS Administration to the skin.
DENTAL Administration to a tooth or teeth.
ENDOCERVICAL Administration within the canal of the cervix uteri.
Synonymous with the term intracervical..
ENDOSINUSIAL Administration within the nasal sinuses of the head.
ENDOTRACHEAL Administration directly into the trachea.
ENTERAL Add inistration directly into the intestines.
EPIDURAL Administration upon or over the dura mater.
EXTRA-AMNIOTIC Administration to the outside of the membrane enveloping the fetus EXTRACORPOREAL Administration outside of the body.
INFILTRATION Administration that results in substances passing into tissue Table I - Routes of Administration Delivery Route Description spaces or into cells.
INTERSTITIAL Administration to or in the interstices of a tissue.
INTRA-ABDOMINAL \dministration within the abdomen.
INTRA-ARTICULAR Administration within a joint.
INTRABILIARY Administration within the bile, bile ducts or gallbladder.
INTRABRONCHIAL Administration within a bronchus.
INTRACARDIAC ;Administration with the heart.
INTRACARTILAGINOUS Administration within a cartilage; endochondral.
INTRACAVERNOUS Administration within a pathologic cavity, such as occurs irr the lung in tuberculosis.
INTRACAVITARY Administration within a non-pathologic cavity, such as that of the cervix, uterus, or penis, or such as that which is formed as the result of a wound.
INTRACEREBRAL Administration within the cerebrum.
INTRACORPORUS CAVERNOSUM Administration within the dilatable spaces of the corporus cavernosa of the penis.
INTRADUCTAL 3 Administration within the duct of a gland.
INTRADUODENAL 'Administration within the duodenum.
INTRADURAL Administration within or beneath the dura.
INTRAESOPHAGEAL Administration within the esophagus.
INTRAGASTRIC Administration within the stomach.
INTRAILEAL Administration within the distal portion of the small intestine, from the jejunum to the cecum.
INTRALESIONAL Administration within or introduced directly into a localized lesion.
INTRALUMINAL Administration within the lumen of a tube.
INTRALYMPHATIC Administration within the lymph.
INTRAMEDULLARY Administration within the marrow cavity of a bone.
INTRAMENINGEAL Administration within the meninges (the three membranes that envelope the brain and spinal cord).
INTRAOCULAR Administration within the eye.
INTRAOVARIAN Administration within the ovary.
Table 2 - Routes of Administration Delivery Route Description INTRAPERICARDIAL Administration within the pericardium.
INTRAPERITONEAL Administration within the peritoneal cavity.
INTRAPLEURAL Administration within the pleura.
INTRAPROSTATIC Administration within the prostate gland.
INTRAPULMOWRY Administration within (lie lungs or its bronchi.
INTRASINAL Administration within the nasal or periorbital sinuses.
INTRASPINAL Administration within the vertebral column.
INTRASYNOVIAL Administration within the synovial cavity of a joint.
INTRATENDINOUS ;administration within a tendon.
JNTRATESTICULAR A dl rn in i stration within the testicle.
INTRATIIECAL Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.
INTRATIIORACIC Administration within the thorax (internal to the ribs);
synonymous with the term endothoracic.
3 INTRATUBULAR Administration within the tubules of an organ.
INTRATUMOR Administration within a tumor.
INTRATYMPANIC Administration within the aurus media.
INTRAUTERINE Administration within the uterus.
INTRAVESICAL Administration within the bladder.
INTRAVITREAL Administration within the vitreous body of the eye.
IRRIGATION :Administration to bathe or flush open wounds or body cavities.
LARYNGEAL -Administration directly upon the larynx.
NASAL Administration to the nose; administered by way of the nose.
NASOGASTRIC Administration through the nose and into the stomach, usually by means of a tube.
OCCLUSIVE DRESSING Administration by the topical route which is then covered by TECHNIQUE a dressing which occludes the area.
OPHTHALMIC Administration to the external eye.
ORAL Administration to or by way of the mouth.
Table 1 - Routes of Administration Delivery Route Description OROPHARYNGEAL Administration directly to the mouth and pharynx.
PERCUTANEOUS Administration through the skin.
PERIARTICULAR Administration around a joint.
PERIDURAL Administration to the outside of the dura mater of the spinal cord..
PERINEURAL Administration surrounding a nerve or nerves.
PERIODONTAL Administration around a tooth.
RECTAL Administration to the rectum.
RESPIRATORY (INHALATION) Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
RETROBULBAR Administration behind the pons or behind the eyeball.
SOFT TISSUE Administration into any soft tissue.
SUBARACHNOID Ad nunistration beneath the ara.chnoid.
SUBCONJUNCTIVAL Administration beneath the conjunctiva.
SUBCUTANEOUS Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL, SUBLINGUAL Administration beneath the tongue.
SUBMUCOSAL Administration beneath the mucous membrane.
TOPICAL Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term.
TRANSMUCOSAL Administration across the mucosa.
TRANSPLACENTAL Administration through or across the placenta.
TRANSTRACHEAL Administration through the wall of the trachea.
TRANSTYMPANIC Administration across or through the tympanic cavity.
F URETERAL ;Adrtninistration into the ureter.
URETHRAL Administration into the urethra.
VAGINAL Administration into the vagina.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
The subject invention provides novel, convenient, inexpensive, and effective drug delivery techniques that utilize, in one embodiment, a device having a reservoir housing and a discharge means for delivering an active agent to a target site. The subject invention also provides compositions and methods of use for the device and composition.
The materials and methods of the subject invention make it possible to conveniently and easily apply fluid containing, for example, a medicinal agent to, for example, a wound. In one embodiment the wound is a surgical site.
As used herein, "active agents" refers to compounds or other entities that perform a therapeutic and/or diagnostic function. This function may be direct, such as promoting tissue repair or killing cancer cells, or may be indirect by eliciting a physiological response that ultimately results in the desired beneficial result.
In one embodiment, a sterile water (not saline) solution comprising 0.05% or less (or even less than 0.04% or even less than 0.03%) of chlorhexidine is applied to a wound in the skin of a human. Preferably the wound is then rinsed within five minutes (preferably within 1-3 )minutes) with a sterile saline or water liquid that does not contain chlorhexidine.
In another embodiment, the solution is applied to a surgical site.
In a specific embodiment, the chlorhexidine gluconate used according to the subject invention has the following chemical structure:
HN
HN H
Chiorhexidine Gluconate Systematic 1- [amino- [6- [amino- [amino-(4-chlorophenyl)amino (JUPAC) Name methylidene]amino-methylidene]aminohexylimino]
methyl] imino-N- (4-chlorophenyl)-methanedi ami ne Chemical Data Formula C22H30C12Nio Mol. weight 505.446 g/rnol In a preferred embodiment, about 15-25 mg of chlorhexidine gluconate is applied to a wound. In one embodiment, the woimd is an abrasion or laceration and the solution is applied prior to repair/closure.
Preferably, the pH of the solution is neutral or slightly acidic. Preferably the pH is 5.0 to 7.5. More preferably the pII is 5.5. to 7Ø In one embodiment, the chlorhexidine is applied without a sudsing agent.
In certain embodiments, the composition does not have any ingredients that would promote microbial growth. Preferably, the composition does not comprise a consistency builder as that term is used in U.S. Published Application 2007/0184114, which is incorporated herein in its entirety.
In specific embodiments, a CHG-containing solution is applied to an open surgical wound. The solution may be applied under pressure or not under pressure. In one embodiment, the solution is not applied by jet lavage. In a further embodiment, the fluid is not applied under pressure. Preferably, the patient is a human. The patient may also be, for example, a dog, horse, cat, pig or cattle.
Preferably, after administration of the CHG solution, the site is washed with saline within 1, 5, or 10 minutes.
In the context of the operating room, the CHG-containing solution is preferably in a sterile container. The container may be sterilized by, for example, irradiation.
In one embodiment, CHG may be provided in a small ampule such that the contents of the ampule can be added to, for example, a standard sized bottle of water, or to an IV bag or line, to create a CHG solution having a concentration of CIIG as described herein.
The solution of the subject invention can also be provided in an IV bag.
In other embodiments, the subject invention provides antimicrobial lotions, creams, sponges, and suppositories. These embodiments preferably contain CHG as the active ingredient.
These embodiments provide CHG, at the concentrations set forth herein, directly to a location wherein antimicrobial activity is needed.
The aqueous solution containing CHG may have other components including, for example, pII modifiers, buffers, local anesthetic agents, agents that promote wound healing (such as agents that help degrade biofilm) and other therapeutic and non-therapeutic compounds. In one embodiment, the composition "consists essentially" of an aqueous solution of CHG, which means that the solution contains no other active agent that materially changes the ability of the solution to control bacteria growth.
In a preferred embodiment, the wound is rinsed with saline after application of a CHG-containing solution. Rinsing with saline not only rinses the CHG off but also the saline chemically neutralizes the CHG thereby preventing or reducing edema. The rinse is preferably applied about 30 seconds to about 5 minutes after the administration of the CHG. The rinse may be from about 100 ml to 1000 ml of saline and is typically applied for about 5 seconds to about 1 minute.
In a preferred embodiment, the application of the irrigation solution of the subject invention results in a reduction in the number of bacteria at the wound when compared to either an untreated wound or a wound irrigated with saline or water that does not contain chlorhexidine.
Advantageously, the use of CHG according to the subject invention can result in effective control of an infection without causing tissue damage.
Advantageously, the irrigation solution of the subject invention i s effective in combating infection, even when organic materials (including blood, tissue, and/or dirt and debris) are present. Of course, such materials are present in all skin wounds.
In addition to killing bacteria, the formulations of the subject invention can also "depathogenize" certain bacteria including, for example, E. coli and Klebsiella aerogenes, making these bacteria less able to cause infection.
Advantageously, the compositions and methods of the subject invention can be used to effectively treat wounds even when biofilm is present.
The drug delivery methods of the subject invention can be used in conjunction with the delivery of an active agent by many of the routes set forth in Table 1. Of particular interest are:
cutaneous, intra-abdominal, intracranial, intralesional, intrathoracic (during surgery), irrigation, nasal, in the ear canal, as an oral bowel prep, for gastric lavage, as an eye wash, periodontal, rectal, soft tissue, subcutaneous, and vaginal routes. The compositions of the subject invention can also be used to control acne and other skin infections, including infections of the feet and scalp. In one embodiment, the chlorhexidine composition of the subject invention is used to treat an abscess. Preferably the solution is applied deep into the abscess using, for example, a device with an elongated discharge port to facilitate effective administration.
Under optimal circumstances, the drug delivery devices and methods of the subject invention are utilized by trained medical technicians; however, because of the simplicity and convenience of the devices of the subject invention, they can be used to greatly enhance the effectiveness of drug delivery regardless of the training level of the operator performing the irrigation.
Delivering Active Agents Examples of agents that can be administered to a patient in accordance with the subject invention include, but are not limited to, anti-bacterial agents, anti-viral agents, fungicidal agents, chemotherapy agents, topical antiseptics, anesthetic agents, oxygenated fluids and/or agents, antibiotics, diagnostic agents, homeopathic agents, and over-the-counter medications/agents.
The target sites to which an active ingredient can be administered according to the subject invention include, but are not limited to, wounds and surgical sites. The surgical sites may include, for example, joint replacements, abdominal surgery, brain surgery, and oral/periodontal surgery sites. In each case, the ability to deliver the active agent to a specific site, at an appropriate dosage, is unique and highly advantageous.
The solution that carries the active agent can be, for example, water, saline, or a balanced salt solution. The solution is preferably sterile. In the case of CHG, the solution is preferably water. The device can be sterilized by known sterilization techniques, including boiling, autoclaving, gas sterilization, irradiation, and the like, either separately or together with the reservoir housing.
The use of chlorhexidine is particularly advantageous because it is broad spectrum, binds to the skin (to provide residual activity), works rapidly and, when used according to the subject invention, is non-toxic.
Chlorhexidine is a chemical antiseptic that can be used to combat both gram positive and gram negative microbes. It is both bacteriostatic and bactericidal. Various species of bacteria are involved in the pathogenesis of wound infection and/or secondary cellulitis.
At times these infections can result in disfigurement, loss of extremities, prolonged convalescences, and/or death. The therapeutic effect of the irrigation solution of the subject invention is to combat microbes typically involved in the pathology of these infections by its antiseptic properties and those associated with the irrigation process itself. Controlling the microbial load in wounds is a vital factor in minimizing infection and thus decreasing and/or preventing disease.
Spectrum of Activity Chlorhexidine is active against aerobic and anaerobic gram-positive and gram-negative bacteria. The drug also has some activity against Chlamydia trachomatis, certain fungi, and certain viruses.
Aerobic Bacteria Chlorhexidine is highly active against a variety of gram-positive aerobic bacteria, including Streptococcus mutans, S pyogenes (group A (3-hemolytic streptococci), S. salivarius, and S. sanguis. Chlorhexidine is active against Staphylococcus aureus, S.
epidermidis, S.
haemolyticus, S. hominis, and S. simulans. The drug is active against both oxacillin-resistant (ORSA) and oxaeillin-susceptible staphylococci (also known as methicillin-resistant [MRSA] or methicillin-susceptible staphylococci). Chlorhexidine is active against Enterococcus, including E. faecalis and E.faecium, and is active against both vancomycin-susceptible and vancomycin-resistant strains.
Anaerobic Bacteria Chlorhexidine is active against some anaerobic bacteria. The drug is active against some strains of Bacteroides, Propionibacterium, Clostridium difficile, and Selenomonas, but is less active against Veillonella.
Fungi Chlorhexidine has some activity against Candida albicans, C. dubliniensis, C.
glabrata (formerly Torulopsis glabrata), C. guillermondii, C. kefyr (formerly C.
pseudotropicalis), C.
krusei, C. lusitaniae, and C. tropicalis (formerly C. parapsilosis).
Chlorhexidine also has some activity against dermatophytes, including Epidermophyton floccosum, Microsporum gypseum, M. cans, and Trichophyton mentagrophytes.
Viruses Chlorhexidine appears to have antiviral activity against viruses that have a lipid component in their outer coat or have an outer envelope such as cytomegalovirus (CMV), human immunodeficiency virus (HIV), herpes simplex virus types 1 (HSV-l) and 2 (HSV-2), influenza virus, parainfluenza virus, and variola virus (smallpox virus).
Methods and Formulations Advantageously, because the methods of the subject invention can be used to accurately and efficiently deliver an active ingredient to a target site in a patient, it is possible, in certain embodiments, to utilize reduced concentrations of active ingredients. Thus, in one embodiment of the subject invention, a low concentration solution of chlorhexidine can be used to effectively reduce infections at, for example, a wound, surgical site, or other tissue opening. In a preferred embodiment, the chlorhexidine solution is less than 4%. In a more preferred embodiment the chlorhexidine is less than 2%, or less than 1 % or even less than 0.1 %. In one embodiment, the chlorhexidine solution is 0.05%. In a further embodiment, the chlorhexidine solution is between 0.02% and 0.05%. Specifically exemplified herein is the use of chlorhexidine gluconate.
As described above, in one embodiment of the subject invention, the device of the subject invention is used to deliver an active agent, such as an antimicrobial agent, to a target site, such as a wound. Subsequent to the administration of the active agent, the site can then be flushed with, for example, saline to remove at least any excess of the active agent.
Preferably, this flushing occurs within five minutes of the administration of the chlorhexidine solution. More preferably, this flushing occurs within one to three minutes of the administration of the chlorhexidine solution. In this way, any potential toxicity associated with the active agent can be reduced or eliminated. In the case of chlorhexidine gluconate, rinsing with an irrigation fluid removes excess chlorhexidine that has not bound to, for example, proteins of the skin.
In yet another embodiment, a diagnostic agent can be administered using the device and method of the subject invention. The diagnostic agent may be, for example, an antibody, protein, or polynucleotide that binds to a target biomolecule. Any such binding may then be visualized utilizing technologies known to those skilled in the art. These technologies include, for example, the use of flourophores or other labels that can be visualized either by the naked eye or through appropriate detection instruments. The diagnostic applications of the subject invention include the detection of bacteria, viruses, parasites and other pathogens.
Cancer cells can also be visualized using the diagnostic methods of the subject invention.
In yet another embodiment, the device and method can be used to deliver growth factors and/or protease inhibitors to a target site. Such growth factors and/or protease inhibitors, which can, for example, expedite the healing of wounds, are well known to those skilled in the art.
In yet another embodiment, the method of the subject invention can be used to deliver oxygenated water and/or "enhanced water" to a target site. The enhanced water can be that which is described in, for example, published U.S. Patent Application 20050191364 and the references cited therein (all of which are incorporated herein by reference in their entireties). The use of the subject method for the effective delivery of such oxygenated or enhanced water can be used to promote tissue healing and reduce infections.
In a further embodiment, the device and method of the subject invention can be used to efficiently deliver anti-microbial peptides (AMPs) to a target site. AMPs are well known in the art. Antimicrobial peptides are predominantly small polypeptides that inhibit the growth of microbes. As effectors of innate immunity, antimicrobial peptides directly kill a broad spectrum of bacteria, fungi, and viruses. In addition, these peptides modify the local inflammatory response and activate mechanisms of cellular and adaptive immunity.
Cathelicidins and defensins comprise the major families of AMPs in the skin, although other cutaneous peptides, such as proteinase inhibitors, chemokines, and neuropeptides, also demonstrate antimicrobial activity. See, for example, Praff, M. et al., (2005) "Cutaneous Defense Mechanisms by Antimicrobial Peptides," .Ilnvest Dermatol, 125:9-13.
The Drug Delivery Device The device of the subject invention can be, for example, the device as shown in U.S.
Published Application No. US-2008-0159963-Al, which is incorporated herein, in its entirety, by reference. The reservoir may be, for example, from 100 ml to 1000 ml.
In one embodiment, the subject invention provides a reservoir housing containing a solution with one or more active agents, wherein the reservoir housing has attached to it a discharge means having one or a plurality of ports through which a sufficient volume of the solution can pass at an appropriate pressure for effective delivery of the solution, including the active agent, to a target site.
The reservoir housing and contents can be stored in a sterile environment, e.g., sterile packaging which is opened immediately prior to use. The reservoir housing can be directed towards the wound and squeezed or compressed to expel or discharge the solution in the desired direction, and at the desired pressure to effect irrigation of a wound to remove contaminants or debris and to deliver the active agent(s).
The discharge means can be packaged separately from the reservoir housing. The discharge means is packaged in a sterile environment. In one embodiment, the drug delivery device is provided in a sterile tray. According to the subject invention, the laceration tray can have, for example, in addition to the drug delivery device of the subject invention, other items conveniently provided for treating wounds. Contemplated items that can be included in a tray include, but are not limited to, needle holders (i.e., 5" floor-grade smooth);
scissors (i.e., 4.5"
floor-grade straight Iris scissors); hemostats (i.e., 5" floor-grade curved mosquito hemostat);
forceps (i.e., floor-grade tissue forceps with 1 x2 teeth); cups (i.e., 2 oz.
medicine cups); syringes (i.e., 10cc Luer Lock syringe); needles (i.e., 25 gauge x 5/8" needle; 27 gauge x 1.5" needle; 18 gauge x 1.5" needle); dressings (i.e., gauze dressings); drapes (i. e., polylined fenestrated drapes);
and towels (i.e., absorbent towels).
Significantly, it is known that more force is required to rid the wound of particles with a small surface area (e.g., bacteria) than to remove particles with a large surface area (e.g., dirt, sand, or vegetation). Minimum recommended volumes of irrigation solution vary, but for a moderately sized potentially contaminated wound, for example a laceration 3-6 cm long and less than 2 cm deep, at least 200 to 500 ml or more should be used. Greater volumes, on the order of 1.
one to two liters, may be required for larger or heavily contaminated wounds.
Irrigation should continue at least until all visible, loose particulate matter has been removed.
Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting.
When a patient presents a wound to a medical or other health care professional skilled in the art, that medical professional assesses the extent of the injury sustained by the patient, including all other life threatening injuries. Appropriate action regarding these life threatening injuries is performed and a history is recorded. All wounds are covered to minimize further contamination until the actual repair process begins.
For examination of the wound, it is assumed that a medical professional would have performed a detailed evaluation of the extent of tissue injury, including but not limited to:
anatomical area considerations, depth of the wound, type of injury, e.g., crash injury, puncture wound, bites, missiles, cuts with sharp objects, or the like. Included in this examination would be a determination of the type(s) of contamination, time elapsed between the occurrence of the injury to presentation, gross contamination of a wound, and other medical factors associated with an increased incidence of infection (for example, diabetics, AIDS patients, and chemotherapeutics patients).
The wound and surrounding tissue, at the option of the health care professional, could be anesthetized using topical, local, or general anesthetics before the wound-cleansing method begins. Alternatively, an anesthetic may be delivered using the device and method of the subject invention.
Manual or mechanically produced pressure is applied to the reservoir housing to expel the irrigation solution with active agent through the nozzles of the discharge means. The wound should be irrigated in this fashion until all visible evidence of contamination has been removed.
A potentially contaminated wound of any size should be irrigated with a minimum of 200-300 ml of irrigation solution. Heavily contaminated or larger wounds may require 2-3 liters of irrigation solution.
ollowing an initial irrigation of the wound, a re-examination of the wound should be undertaken. The wound should be explored to its base to ascertain that no visible foreign bodies or contaminants remain. If foreign bodies or contaminants are found, the irrigation process should be repeated followed by a re-examination. This may continue for several cycles.
Once irrigation has been completed, i.e., no visible contaminants remain, the damaged tissue would be repaired in a standard accepted fashion.
Irrigation of skin wounds such as cuts, scrapes, punctures, abrasions, etc.
are particularly well-suited for irrigation according to the subject invention, as is irrigation of surgical sites.
Table 1 provides a listing of various routes of administration that can be used according to the subject invention.
Table 1 - Routes of Administration Delivery Route Description AURICULAR (OTIC) Adm ire iistration to or by way of the ear.
BUCCAL Administration directed toward the cheek, generally from within the mouth.
CONJUNCTIVAL Administration to the conjunctiva, the delicate membrane that lines the eyelids and covers the exposed surface of the eyeball.
CUTANEOUS Administration to the skin.
DENTAL Administration to a tooth or teeth.
ENDOCERVICAL Administration within the canal of the cervix uteri.
Synonymous with the term intracervical..
ENDOSINUSIAL Administration within the nasal sinuses of the head.
ENDOTRACHEAL Administration directly into the trachea.
ENTERAL Add inistration directly into the intestines.
EPIDURAL Administration upon or over the dura mater.
EXTRA-AMNIOTIC Administration to the outside of the membrane enveloping the fetus EXTRACORPOREAL Administration outside of the body.
INFILTRATION Administration that results in substances passing into tissue Table I - Routes of Administration Delivery Route Description spaces or into cells.
INTERSTITIAL Administration to or in the interstices of a tissue.
INTRA-ABDOMINAL \dministration within the abdomen.
INTRA-ARTICULAR Administration within a joint.
INTRABILIARY Administration within the bile, bile ducts or gallbladder.
INTRABRONCHIAL Administration within a bronchus.
INTRACARDIAC ;Administration with the heart.
INTRACARTILAGINOUS Administration within a cartilage; endochondral.
INTRACAVERNOUS Administration within a pathologic cavity, such as occurs irr the lung in tuberculosis.
INTRACAVITARY Administration within a non-pathologic cavity, such as that of the cervix, uterus, or penis, or such as that which is formed as the result of a wound.
INTRACEREBRAL Administration within the cerebrum.
INTRACORPORUS CAVERNOSUM Administration within the dilatable spaces of the corporus cavernosa of the penis.
INTRADUCTAL 3 Administration within the duct of a gland.
INTRADUODENAL 'Administration within the duodenum.
INTRADURAL Administration within or beneath the dura.
INTRAESOPHAGEAL Administration within the esophagus.
INTRAGASTRIC Administration within the stomach.
INTRAILEAL Administration within the distal portion of the small intestine, from the jejunum to the cecum.
INTRALESIONAL Administration within or introduced directly into a localized lesion.
INTRALUMINAL Administration within the lumen of a tube.
INTRALYMPHATIC Administration within the lymph.
INTRAMEDULLARY Administration within the marrow cavity of a bone.
INTRAMENINGEAL Administration within the meninges (the three membranes that envelope the brain and spinal cord).
INTRAOCULAR Administration within the eye.
INTRAOVARIAN Administration within the ovary.
Table 2 - Routes of Administration Delivery Route Description INTRAPERICARDIAL Administration within the pericardium.
INTRAPERITONEAL Administration within the peritoneal cavity.
INTRAPLEURAL Administration within the pleura.
INTRAPROSTATIC Administration within the prostate gland.
INTRAPULMOWRY Administration within (lie lungs or its bronchi.
INTRASINAL Administration within the nasal or periorbital sinuses.
INTRASPINAL Administration within the vertebral column.
INTRASYNOVIAL Administration within the synovial cavity of a joint.
INTRATENDINOUS ;administration within a tendon.
JNTRATESTICULAR A dl rn in i stration within the testicle.
INTRATIIECAL Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.
INTRATIIORACIC Administration within the thorax (internal to the ribs);
synonymous with the term endothoracic.
3 INTRATUBULAR Administration within the tubules of an organ.
INTRATUMOR Administration within a tumor.
INTRATYMPANIC Administration within the aurus media.
INTRAUTERINE Administration within the uterus.
INTRAVESICAL Administration within the bladder.
INTRAVITREAL Administration within the vitreous body of the eye.
IRRIGATION :Administration to bathe or flush open wounds or body cavities.
LARYNGEAL -Administration directly upon the larynx.
NASAL Administration to the nose; administered by way of the nose.
NASOGASTRIC Administration through the nose and into the stomach, usually by means of a tube.
OCCLUSIVE DRESSING Administration by the topical route which is then covered by TECHNIQUE a dressing which occludes the area.
OPHTHALMIC Administration to the external eye.
ORAL Administration to or by way of the mouth.
Table 1 - Routes of Administration Delivery Route Description OROPHARYNGEAL Administration directly to the mouth and pharynx.
PERCUTANEOUS Administration through the skin.
PERIARTICULAR Administration around a joint.
PERIDURAL Administration to the outside of the dura mater of the spinal cord..
PERINEURAL Administration surrounding a nerve or nerves.
PERIODONTAL Administration around a tooth.
RECTAL Administration to the rectum.
RESPIRATORY (INHALATION) Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
RETROBULBAR Administration behind the pons or behind the eyeball.
SOFT TISSUE Administration into any soft tissue.
SUBARACHNOID Ad nunistration beneath the ara.chnoid.
SUBCONJUNCTIVAL Administration beneath the conjunctiva.
SUBCUTANEOUS Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL, SUBLINGUAL Administration beneath the tongue.
SUBMUCOSAL Administration beneath the mucous membrane.
TOPICAL Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term.
TRANSMUCOSAL Administration across the mucosa.
TRANSPLACENTAL Administration through or across the placenta.
TRANSTRACHEAL Administration through the wall of the trachea.
TRANSTYMPANIC Administration across or through the tympanic cavity.
F URETERAL ;Adrtninistration into the ureter.
URETHRAL Administration into the urethra.
VAGINAL Administration into the vagina.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
Claims (20)
1. A sterile container having contained therein a sterile aqueous solution comprising chlorhexidine at a concentration of 0.05% or less.
2. The container, according to claim 1, which contains from 100 ml to 1000 ml of said solution.
3. The container, according to claim 1, wherein said container further comprises a backsplash shield.
4. The container, according to claim 1, wherein the chlorhexidine is present at a concentration of 0.05 %.
5. The container, according to claim 1, wherein the chlorhexidine is in the form of chlorhexidine gluconate.
6. A method for irrigating a wound, said method comprising applying the contents of the container of claim 1 to a wound.
7. The method, according to claim 6, wherein said device further comprises a backsplash shield.
8. The method, according to claim 6, further comprising rinsing the wound within 5 minutes with a solution that does not contain chlorhexidine.
9. The method, according to claim 6, used to treat a wound in a human.
10. The method, according to claim 6, wherein the chlorhexidine is at a concentration of 0.05%.
11. The method, according to claim 6, used to irrigate a surgery site.
12. The method, according to claim 11, where the type of surgery is selected from the group consisting of orthopedic, cardiac, brain, and abdominal surgeries.
13. The method, according to claim 6, used to treat a MRSA infection.
14. The method, according to claim 13, wherein the presence of MRSA is know-ii prior to the administration of the solution.
15. The method, according to claim 6, used to treat an abscess.
16. An ampule containing a solution of chlorhexidine at a concentration such that, when the contents of the ampule is mixed with a known volume of water ranging from 250 ml to 5 liters, the resulting solution has a chlorhexidine concentration of less than 1.0%.
17. A cream, lotion, sponge, suppository, or coated indwelling medical device that delivers, to a site of infection, chlorhexidine at a concentration of 0.05% or less.
18. Use of a composition of claim 17 to control an infection.
19. A kit comprising a container according to claim 1 as well as a container of saline.
20. The kit, according to claim 19, which is sterile.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25490609P | 2009-10-26 | 2009-10-26 | |
US61/254,906 | 2009-10-26 | ||
PCT/US2010/053884 WO2011056486A2 (en) | 2009-10-26 | 2010-10-24 | Devices, methods, and composition for controlling infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2778081A1 true CA2778081A1 (en) | 2011-05-12 |
Family
ID=43970646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2778081A Abandoned CA2778081A1 (en) | 2009-10-26 | 2010-10-24 | Devices, methods, and composition for controlling infections |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2493442A4 (en) |
JP (1) | JP2013508457A (en) |
CN (1) | CN102711709A (en) |
CA (1) | CA2778081A1 (en) |
WO (1) | WO2011056486A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5872430B2 (en) * | 2012-09-20 | 2016-03-01 | 日本電子照射サービス株式会社 | Chlorhexidine gluconate formulation, disinfection kit and sterilization method |
US10016375B2 (en) | 2013-12-12 | 2018-07-10 | Paul J. Rucinski | Materials and methods for controlling infections |
US9642820B2 (en) * | 2013-12-12 | 2017-05-09 | Innovation Technologies, Inc. | Materials and methods for controlling infections |
WO2016022441A1 (en) * | 2014-08-08 | 2016-02-11 | Innovation Technologies, Inc. | Materials and methods for controlling infections with negative pressure wound therapy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9616208D0 (en) * | 1996-08-01 | 1996-09-11 | Smithkline Beecham Plc | Novel Compounds |
US6017516A (en) * | 1997-10-31 | 2000-01-25 | Lekar Pharma Limited | Pharmaceutical dental formulation for topical application of metronidazole benzoate and chlorhexidine gluconate |
US20040185028A1 (en) * | 2003-03-19 | 2004-09-23 | Zhenze Hu | Antimicrobial compositions containing ethanolamine buffer and biguanide disinfectant |
MXPA06003155A (en) * | 2003-09-22 | 2006-06-05 | Innovation Technologies Inc | Wound i/rrigation device and method. |
US20050124946A1 (en) * | 2003-12-05 | 2005-06-09 | Sergio Landau | Wound irrigation apparatus and method |
WO2005084627A1 (en) * | 2004-03-01 | 2005-09-15 | University Of Iowa Research Foundation | Alcohol-free chlorhexidine compositions |
US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
JP2006117587A (en) * | 2004-10-22 | 2006-05-11 | Dainippon Sumitomo Pharma Co Ltd | Germicidal disinfectant composition |
US20070036846A1 (en) * | 2005-08-15 | 2007-02-15 | Tsang Wing W M | Wound dressing and method of manufacture thereof |
US7540860B2 (en) * | 2006-01-23 | 2009-06-02 | Keith Stamler | Wound irrigation splashback shield |
NZ577695A (en) * | 2006-12-19 | 2012-02-24 | Innovation Technologies Inc | Wound irrigation device comprising chlorhexidine |
-
2010
- 2010-10-24 EP EP10828816.8A patent/EP2493442A4/en not_active Ceased
- 2010-10-24 CA CA2778081A patent/CA2778081A1/en not_active Abandoned
- 2010-10-24 CN CN201080048369XA patent/CN102711709A/en active Pending
- 2010-10-24 WO PCT/US2010/053884 patent/WO2011056486A2/en active Application Filing
- 2010-10-24 JP JP2012536912A patent/JP2013508457A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102711709A (en) | 2012-10-03 |
WO2011056486A3 (en) | 2011-09-29 |
EP2493442A4 (en) | 2013-05-15 |
EP2493442A2 (en) | 2012-09-05 |
WO2011056486A2 (en) | 2011-05-12 |
JP2013508457A (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11559503B2 (en) | Materials and methods for controlling infections | |
US7662125B2 (en) | Devices and methods for delivering active agents to target sites | |
US20210154158A1 (en) | Devices, methods, and compositions for controlling infections | |
EP3117849B1 (en) | Devices and solutions for delivering active agents to target sites | |
CA2778081A1 (en) | Devices, methods, and composition for controlling infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20221207 |
|
FZDE | Discontinued |
Effective date: 20221207 |